Added to YB: 2025-10-22
Pitch date: 2025-09-04
MEDXF [bullish]
Medexus Pharmaceuticals Inc.
-14.43%
current return
Author Info
No bio for this author
Company Info
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases.
Market Cap
CAD 62.3M
Pitch Price
CAD 3.05
Price Target
13.77 (+428%)
Dividend
N/A
EV/EBITDA
4.50
P/E
67.58
EV/Sales
0.71
Sector
Pharmaceuticals
Category
growth
Medexus Pharmaceuticals Inc. - $MEDXF
MEDXF: Specialty pharma w/ Grafapex (Treosulfan) just approved for US launch Q2 2025, targeting $100M revenue by 2030 at 80% gross margins vs current 55%. Base business declining -2% CAGR but company trades 4.6x LTM EV/EBITDA, 1.2x 2029E EBITDA. Risks: tariffs, execution, base business headwinds.
Read full article (8 min)